The vaccine is developed by U.S. pharmaceutical company, Merck & Co. Inc. has proven to be 100 percent effective against the two major strains of the Human Papilloma Virus (HPV).
The U.S. Food and Drug Administration (FDA) approved the vaccine last month.
The European company marketing Gardasil, Sanofi Pasteur MSD, got a "positive opinion" from the Committee for Medicinal Products for Human Use following application for a license.
The European Commission is expected to grant permission for Gardasil's release in September - making it available three months ahead of schedule.
The National Cancer Coalition points out that 4000 women die each year as a result of cervical cancer. Additionally, 300,000 women die worldwide.
Gardasil protects against four HPV strains as well as other conditions caused by the virus, including genital warts.
Although the costs have not yet been determined, analysts say that it could mount up to more that $100 a dose, with three doses necessary for the required treatment.
Another vaccine for cervical cancer, known as Cervarix made by GlaxoSmithKline, is undergoing the licensing process. It was submitted for a license in March, and is expected to go through a period of three months to get to the where Gardasil is now.
